NCT06043765
Reducing Cognitive Impairment in Glioma with Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
Recruiting · Not Applicable · Linda Douw · registry updated 2024-11-18
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The TRUE-GRIT study will assess the feasibility of a study protocol investigating the efficacy of a combination therapy consisting of cognitive strategy training (CST) and repetitive transcranial magnetic stimulation (rTMS) to reduce cognitive impairment in adult glioma patients. This study is part of the GRIP-project, a project aimed at investigating interventions for improving quality of life in brain tumor patients.
Inclusion
- ≥ 18 years of age
- Histological diagnosis of diffuse glioma (WHO grade 2,3, or 4)
- Subjective cognitive impairment, defined as CFQ-score ≥ 44
- Being able to give informed consent and undergo treatment and measurements based on researchers insight
- Stable disease, i.e. no oncological treatment for ≤ 2 months prior to inclusion; no radiological progression on the most recent MRI, not older than 6 months, and no clinical progression at inclusion
- Stable dosage (for at least 8 weeks) of anti-epileptic medication
Exclusion
- Current pregnancy or have given birth less than three months ago
- Current other treatment for cognitive complaints
- Karnofsky performance score \<70
- A tumor located in the parietal cortex
- TMS exclusion: implanted medical devices (e.g. pacemaker, deep brain stimulator, cochlear implants, medical infusion device, etc.); metal in the body; sleep deprivation
- MRI exclusion: extreme claustrophobia or metallic objects in or on the body